The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
作者： V Munugalavadla , S Mariathasan , D Slaga , C Du , L Berry
DOI: 10.1038/ONC.2012.594
关键词:
摘要: The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
elsevier.com
nature.com
sci-hub.se 参考文章(37)
Morris E. Feldman, Kevan M. Shokat, New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). Current Topics in Microbiology and Immunology. ,vol. 347, pp. 241- 262 ,(2010) , 10.1007/82_2010_64
Asim Khwaja, PI3K as a Target for Therapy in Haematological Malignancies Current Topics in Microbiology and Immunology. ,vol. 347, pp. 169- 188 ,(2010) , 10.1007/82_2010_71
Asher A. Chanan-Khan, Ivan Borrello, Kelvin P. Lee, Donna E. Reece, Development of target-specific treatments in multiple myeloma. British Journal of Haematology. ,vol. 151, pp. 3- 15 ,(2010) , 10.1111/J.1365-2141.2010.08262.X
Michael Hallek, P. Leif Bergsagel, Kenneth C. Anderson, Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process Blood. ,vol. 91, pp. 3- 21 ,(1998) , 10.1182/BLOOD.V91.1.3
Angela Zöllinger, Thorsten Stühmer, Manik Chatterjee, Stefan Gattenlöhner, Eugenia Haralambieva, Hans-Konrad Müller-Hermelink, Mindaugas Andrulis, Axel Greiner, Carmen Wesemeier, Jörg C. Rath, Hermann Einsele, Ralf C. Bargou, Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma Blood. ,vol. 112, pp. 3403- 3411 ,(2008) , 10.1182/BLOOD-2007-11-119362
Jie Zhang, Yong Choi, Blanche Mavromatis, Alan Lichtenstein, Weiqun Li, Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway Oncogene. ,vol. 22, pp. 6289- 6295 ,(2003) , 10.1038/SJ.ONC.1206718
Philipp Baumann, Sonja Mandl-Weber, Fuat Oduncu, Ralf Schmidmaier, The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma Experimental Cell Research. ,vol. 315, pp. 485- 497 ,(2009) , 10.1016/J.YEXCR.2008.11.007
Mohamed Rahmani, Anh Anderson, Joseph Reza Habibi, Timothy Ryan Crabtree, Mandy Mayo, Hisashi Harada, Andrea Ferreira-Gonzalez, Paul Dent, Steven Grant, The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood. ,vol. 114, pp. 4507- 4516 ,(2009) , 10.1182/BLOOD-2008-09-177881
Kiyotaka Kawauchi, Toshie Ogasawara, Masako Yasuyama, Kuniaki Otsuka, Osamu Yamada, The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anti-cancer Agents in Medicinal Chemistry. ,vol. 9, pp. 550- 559 ,(2009) , 10.2174/187152009788451851
Douglas W. McMillin, Melissa Ooi, Jake Delmore, Joseph Negri, Patrick Hayden, Nicolas Mitsiades, Jana Jakubikova, Sauveur-Michel Maira, Carlos Garcia-Echeverria, Robert Schlossman, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades, Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Cancer Research. ,vol. 69, pp. 5835- 5842 ,(2009) , 10.1158/0008-5472.CAN-08-4285